Form 4: Baxter EVP Granted Equity, Reports Tax Withholding

Baxter International's EVP and General Counsel, David S. Rosenbloom, received new equity grants and reported shares withheld for tax obligations.

Summary

• David S. Rosenbloom, Executive Vice President and General Counsel of Baxter International Inc. (BAX), reported several transactions.
• On February 27, 2026, Rosenbloom received a grant of 26,709 restricted stock units (RSUs) at a price of $0.
• These RSUs are scheduled to vest in three equal annual installments beginning on March 1, 2027, subject to satisfaction of vesting requirements.
• Also on February 27, 2026, Rosenbloom was granted 64,655 stock options with an exercise price of $20.37.
• These stock options become exercisable in three equal annual installments starting on March 1, 2027, and have an expiration date of February 27, 2036.
• On March 2, 2026, 1,336 shares of common stock were forfeited by Rosenbloom to cover tax withholding obligations incurred from the settlement of vested restricted stock units granted on March 1, 2023, at a price of $19.69 per share.
• Following these reported transactions, Rosenbloom directly beneficially owns 144,837 shares of common stock and 64,655 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine executive compensation disclosure that aligns management's interests with shareholders through equity grants, which is generally a positive for corporate governance and long-term value creation.

Positives

• The grant of 26,709 restricted stock units and 64,655 stock options aligns the executive's long-term interests with those of shareholders.
• Equity grants are a standard component of executive compensation, designed to incentivize performance and retention of key management.

Negatives

• The forfeiture of 1,336 shares for tax withholding is a routine event upon the vesting of equity awards and does not indicate a negative operational or financial outcome for the company.

Future Outlook

The newly granted restricted stock units are scheduled to vest in three equal annual installments beginning March 1, 2027. The newly granted stock options will become exercisable in three equal annual installments starting March 1, 2027, and will expire on February 27, 2036.

Industry Context

StockSavvy.ai notes that executive equity grants, such as restricted stock units and stock options, are a common practice across the healthcare and medical device industry. These compensation structures are designed to align the long-term interests of executives with those of shareholders, fostering sustained performance and retention in a competitive talent landscape.

Stakeholder Impact

• Shareholders: The equity grants align the executive's financial incentives with the company's long-term performance, potentially benefiting shareholder value.
• Employees (specifically the reporting person): The grants represent a significant component of the executive's compensation package, incentivizing continued service and performance.

Next Steps

• The restricted stock units will vest in three equal annual installments beginning March 1, 2027.
• The stock options will become exercisable in three equal annual installments beginning March 1, 2027.

Key Dates

Keywords

Baxter International, BAX, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Corporate Governance